Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Sponsor: Eli Lilly and Company
Summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Official title: A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
787
Start Date
2025-05-20
Completion Date
2032-12
Last Updated
2026-03-02
Healthy Volunteers
No
Interventions
Pirtobrutinib
Administered orally.
Locations (38)
Cancer Specialists, LLC
Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Florida Cancer Specialists
Sarasota, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic- Minnesota
Rochester, Minnesota, United States
University Of Nebraska Medical Center
Omaha, Nebraska, United States
Cayuga Cancer Center
Ithaca, New York, United States
Northwell Health
Lake Success, New York, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
Tennessee Oncology
Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Swedish Cancer Institute
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Flinders Medical Centre
Adelaide, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Linear Clinical Research
Victoria, Australia
CHU de Nantes - Hotel Dieu
Nantes, France
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
Bologna, Italy
Ospedale San Raffaele
Milan, Italy
Nagoya Medical Center
Aichi-Ken, Japan
National Cancer Center Hospital
Cho-ku, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Tokai University Hospital- Isehara Campus
Isehara, Japan
Tohoku University Hospital
Miyagi-Ken, Japan
Hokkaido University Hospital
Sapporo, Japan
Pratia MCM Krakow
Krakow, Poland
Instytut Hermatologii I Transfuzjologii
Warsaw, Poland
Seoul National University Hospital
Seoul, South Korea
St James's University Hospital
Leeds, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Derriford Hospital
Plymouth, United Kingdom